| Chronic rhinosinusitis with multiple nasal polyps

Nucala vs Xolair

Side-by-side clinical, coverage, and cost comparison for chronic rhinosinusitis with multiple nasal polyps.

Deep comparison between: Nucala vs Xolair with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXolair has a higher rate of injection site reactions vs Nucala based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xolair but not Nucala, including UnitedHealthcare

Category

Nucala

Xolair

At A Glance

RouteSC injection

FrequencyEvery 4 weeks

ClassIL-5 antagonist

RouteSC injection

FrequencyEvery 2-4 weeks

ClassAnti-IgE antibody

Indications

Asthma
Chronic rhinosinusitis with multiple nasal polyps
Chronic Obstructive Airway Disease
Eosinophilic granulomatosis with polyangiitis
Hypereosinophilic syndrome

Asthma
Chronic rhinosinusitis with multiple nasal polyps
IgE-mediated food allergy
Chronic Spontaneous Urticaria

Dosing

Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.

Asthma (6-11 years) 40 mg SC once every 4 weeks.

Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.

Asthma 75 to 375 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).

Chronic rhinosinusitis with multiple nasal polyps 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).

IgE-mediated food allergy 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).

Chronic Spontaneous Urticaria 150 or 300 mg SC every 4 weeks; dosing is not dependent on serum IgE level or body weight.

Contraindications

History of hypersensitivity to mepolizumab or excipients in the formulation

Severe hypersensitivity reaction to omalizumab or any ingredient of XOLAIR

Drug Interactions

379View drug interactions

164View drug interactions

Adverse Reactions

Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema

Serious herpes zoster

Postmarketing hypersensitivity reactions including anaphylaxis

Most common (>=1%) Arthralgia, pain, injection site reactions, headache, fatigue, dizziness, pruritus, nasopharyngitis, sinusitis, upper respiratory tract infection, dermatitis, earache

Serious Anaphylaxis, malignancies, cardiovascular and cerebrovascular events

Postmarketing Anaphylaxis, eosinophilic conditions, fever with arthralgia and rash (serum sickness-like), severe thrombocytopenia, hair loss

Pharmacology

Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.

Omalizumab is a recombinant humanized IgG1 monoclonal antibody that inhibits the binding of IgE to high-affinity IgE receptors (FceRI) on mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation and reduction of IgE-mediated inflammatory responses; in CSU, omalizumab binds to IgE and lowers free IgE levels with down-regulation of IgE receptors, though the exact mechanism by which this results in CSU symptom improvement is unknown.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Nucala